Viking Therapeutics, Inc.
VKTXW
VKTXW was delisted on the 8th of April, 2021.
4 hedge funds and large institutions have $665K invested in Viking Therapeutics, Inc. in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 2 → 4 (+2)
58% more capital invested
Capital invested by funds: $422K → $665K (+$243K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$44.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$292 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PWAM
1
Park West Asset Management
San Francisco,
California
| $398K | – | – | – |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $219K | +$746K | +163,536 | New |
|
|
3
Morgan Stanley
New York
| $40K | +$44.2K | +9,700 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $8K | +$292 | +64 | +3% |
|
VKTXW Hedge Fund Activity: Q4 2020 in Review
4 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics, Inc. (VKTXW) for Q4 2020, worth a combined $665K — up 58% from $422K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VKTXW positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $44.2K.
- 4 institutional investors held Viking Therapeutics, Inc. (VKTXW) as of Q4 2020, up from 2 in Q3 2020.
- Funds reported $665K of Viking Therapeutics, Inc. stock for Q4 2020, up 58% quarter-over-quarter.
- 2 funds opened new Viking Therapeutics, Inc. positions in Q4 2020 and 0 closed out, a net change of +2 holders.
- The largest Viking Therapeutics, Inc. buyer in Q4 2020 was Morgan Stanley, an estimated $44.2K added.
Based on aggregated 13F filings for Q4 2020.